

12[™] ANNUAL SCIENTIFIC SYMPOSIUM

A CME/CNE - Certified Conference

BRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer

Keynote Speaker and Basser Global Prize Awardee: Kenneth Offit, MD, MPH

MONDAY, MAY 13 — TUESDAY, MAY 14, 2024

Smilow Center for Translational Research Auditorium/Commons (enter through Perelman Center for Advanced Medicine)



Program Overview

This hybrid symposium is designed to educate researchers, scientists, and health care providers in cancer genetics by presenting cutting-edge data from renowned researchers and clinicians. This symposium will provide new information on progress in cancer screening and prevention, as well as ongoing work in targeted therapy for *BRCA1/2* and other mutation carriers through a series of lectures and panel discussions.

PROGRAM OBJECTIVES

At the completion of this symposium, attendees should be able to:

- Discuss new research on the genetic epidemiology of *BRCA1/2* and other homologous recombination deficiency (HRD) genes.
- Describe current ethical, legal and social issues associated with carrying a *BRCA1/2* mutation.
- Review new approaches to screening and prevention of hereditary breast, ovarian, pancreatic and prostate cancer.
- Discuss new advances in treatment for mutation carriers of *BRCA1/2* and other known cancer susceptibility genes.

WHO SHOULD ATTEND

Healthcare providers including medical oncology, surgical oncology, gynecology oncology, OB-GYN, genetic counselors, primary care physicians, physician assistants and nurses/nurse practitioners who are interested in the genetics of *BRCA1/2* related cancers.

The symposium is sponsored in part by a generous gift from Margaret I. Cuomo and Howard Maier.



KEYNOTE SPEAKER AND BASSER GLOBAL PRIZE AWARDEE Kenneth Offit, MD, MPH

The Basser Center is honored to announce Kenneth Offit, MD, MPH

Chief, Clinical Genetics Service Memorial Sloan Kettering Cancer Center

at hereditary risk for breast and ovarian cancer.

of Memorial Sloan Kettering Cancer Center, is the recipient of the 12th annual Basser Global Prize. Dr. Offit is the Robert and Kate Niehaus Chair in Inherited Cancer Genomics and serves as Chief of the Clinical Genetics Service at MSKCC. Dr. Offit received his MD and MPH from Harvard University. Dr. Offit's work identified the most common mutation associated with an increased risk of breast, ovarian, and prostate cancer among individuals

of Ashkenazi Jewish ancestry He also published the first prospective series

describing the outcome of preventive ovarian surgery and screening in women

Dr. Offit founded one of the first clinical cancer genetics services in 1992 and led the first American Society of Clinical Oncology policy statement after the identification of the BRCA1 and BRCA2 genes. His ongoing research includes leading an implementation study, funded by the National Institutes of Health, to pilot health dissemination of genomic information.



Symposium Chair
Susan M. Domchek, MD

Executive Director, Basser Center for BRCA
Director, Mariann and Robert MacDonald Cancer Risk Evaluation Center

Susan Domchek is the Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. She serves as

Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center. Her work focuses on the genetic evaluation and medical management of individuals with inherited risk factors for cancer. Dr. Domchek is particularly interested in developing new cancer therapies, such as PARP inhibitors, for patients with genetic risk factors. An elected member of the National Academy of Medicine, Dr. Domchek is also a significant contributor to the oncology literature. She has authored/co-authored more than 400 articles appearing in scholarly journals including the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology, among others.

SYMPOSIUM CO-ORGANIZERS

Ronald Drapkin, MD, PhD

Franklin Payne Associate Professor of Pathology in Obstetrics & Gynecology

Director, Penn Ovarian Cancer Research Center

Director of Gynecologic Cancer Research,

Basser Center for BRCA

Dana Farengo Clark, MS, MS, LCGC

Senior Genetic Counselor

Mariann & Robert MacDonald Cancer Risk

Evaluation Center

Basser Center for BRCA

Adam Fredo, PA-C

Physician Assistant

Medical Oncology

Penn Medicine

Roger Greenberg, MD, PhD

J. Samuel Staub, MD, Professor, Department of Cancer Biology

Director, Penn Center for Genome Integrity (PCGI)

Director of Basic Science, Basser Center for BRCA

Mosetta Harris, CRNP

Nurse Practitioner

Rena Rowan Breast Center

Penn Medicine

Katherine Nathanson, MD

Pearl Basser Professor of BRCA-Related Research
Deputy Director, Abramson Cancer Center
Director of Genetics, Basser Center for BRCA

PENN MEDICINE FACULTY

Jessica Ebrahimzadeh, MS, LCGC

Genetic Counselor

Mariann & Robert MacDonald Cancer Risk

Evaluation Center

Basser Center for BRCA

Derek Mann, MS, LCGC

Genetic Counselor

Mariann & Robert MacDonald Cancer Risk

Evaluation Center

Basser Center for BRCA

Ben Stanger, MD, PhD

Hanna Wise Professor in Cancer Research
Director, Penn Pancreatic Cancer Research Center

GUEST SPEAKERS

Samuel Bakhoum, MD, PhD

Associate Attending Radiation Oncologist Memorial Sloan Kettering Cancer Center

Jennifer Guerriero, PhD

Assistant Professor, Harvard Medical School Lead Investigator, Brigham and Women's Hospital Breast Cancer Program, Dana-Farber/Harvard Cancer Center

Harvard Immunology, Harvard Medical School

Jada Hamilton, PhD, MPH

Co-Director, Genomics, Risk & Health Decision-Making Laboratory

Associate Attending Psychologist, Department of Psychiatry & Behavioral Sciences

Clinical Genetics Service, Department of Medicine Memorial Sloan Kettering Cancer Center

Kai Kessenbrock, PhD

Associate Professor, Biological Chemistry Chao Family Comprehensive Cancer Center University of California, Irvine

Hendrik Messal. PhD

Senior Postdoctoral Researcher The Netherlands Cancer Institute

Kenneth Olive, PhD

Associate Professor of Medicine Columbia University Irving Medical Center

John Richardson

Director of Policy and Government Affairs

National Society of Genetic Counselors (NSGC)

Mark Robson, MD

Chief, Breast Medicine Service Clinic Director, Clinical Genetics Service Memorial Sloan Kettering Cancer Center

Sven Rottenberg, DVM, PhD, Dipl. ECVP

Department Chair, Department of Infectious Diseases and Pathobiology (DIP), Vetsuisse Faculty, University of Bern

Violeta Serra, PhD

Group Leader, Experimental Therapeutics Group
Miguel Servet Investigator
Vall D'Hebron Institute of Oncology, Barcelona Spain

Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH

Professor of Translational Cancer Genetics | Institute of Cancer Research NHS Consultant in Clinical Cancer Genetics (Honorary) | Royal Marsden NHS Foundation Trust Consultant in Public Health Medicine (Honorary)| Public Health England

Laura Valle, PhD

Principal Investigator
Hereditary Cancer Program
Catalan Institute of Oncology, IDIBELL
Barcelona, Spain

Gilbert Welch, MD, MPH

Center for Surgery and Public Health Brigham and Women's Hospital

Gerburg Wulf, MD, PhD

Associate Professor of Medicine, Harvard Medical School Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center

Dmitriy Zamarin, MD, PhD

Associate Professor
Section Head, Gynecologic Medical Oncology
Precision Immunology Institute
Icahn School of Medicine at Mount Sinai

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

MONDAY, MAY 13, 2024

7:30-8:15am Registration

8:15-8:30am Welcome

Morning Session

8:30-9:00am Kai Kessenbrock, PhD

Understanding the role of the microenvironment in BRCA1-driven

breast tumorigenesis

9:00-9:30am Samuel Bakhoum, MD, PhD

Chromosomal instability as a source of tumor-promoting inflammation

9:30-10:00am Kenneth Olive, PhD

Targeting and preventing pancreatic cancer BRCA2-mutant mouse models

10:00-10:30am BREAK

10:30-11:00am Jennifer Guerriero, PhD

Targeting immunosuppressive macrophages overcomes PARP inhibitor

resistance in BRCA1-associated triple-negative breast cancer

11:00-11:30am Hendrik Messal, PhD

A high burden of abnormal cell behavior in disease-free human breasts

11:30-12:00pm Roger Greenberg, MD, PhD

Targeting homologous recombination deficient cancers

12:00-1:15pm LUNCH

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

MONDAY, MAY 13, 2024

Afternoon Session

1:15-1:45pm Ben Stanger, MD, PhD

Personalized models and interception strategies for pancreatic cancer

1:45-2:15pm Dmitriy Zamarin, MD, PhD

Overcoming immune heterogeneity in ovarian cancer

2:15-2:45pm Violeta Serra, PhD

HRD beyond BRCA1/2 and the need of functional biomarkers

2:45-3:15pm Sven Rottenberg, DVM, PhD, Dipl. ECVP

Mechanisms of genetic reversion-independent chemoresistance in

BRCA1/2-mutated tumors

3:15-3:45pm Gerburg Wulf, MD, PhD

A short course of olaparib combinations for the prevention of

BRCA1-realted breast cancer

End of accredited portion

4:00-5:00pm Poster Session

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

TUESDAY, MAY 14, 2024

7:30-8:15am Registration

8:15-8:30am Welcome

Morning Session

8:30-9:00am Gilbert Welch, MD

Multicancer early detection screening: Challenges posed by birds,

rabbits, and turtles

9:00-9:30am Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH

Population genomic risk stratification to inform cancer screening

9:30-10:00am Mark Robson, MD

Update on treatment of hereditary breast cancer

10:00-10:30am BREAK

10:30-11:00am Laura Valle, PhD

APC 11307K and cancer risk: Recommendations of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) for classification of the

variant, cancer screening, and predictive testing

11:00-11:30am Katherine Nathanson, MD

Comprehensive analysis of the landscape of reversion mutations in HR genes

11:30-12:00pm Jada Hamilton, PhD, MPH

Implications of polygenic risk scores for risk-reducing mastectomy

decision-making experiences among BRCA1/2 carriers

12:00-1:15pm LUNCH

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

TUESDAY, MAY 14, 2024

A C.				
Att	tern	oon	Ses	sion

1:15-1:45pm John Richardson

Genetic Counselor advocacy update: State licensure and Medicare

provider status

1:45-2:15pm Derek Mann, MS, LCGC

Year in review: Updates and trends in hereditary cancer genetic counseling

2:15-3:00pm Case Panel moderated by Susan Domchek, MD with:

Jessica Ebrahimzadeh MS, LCGC, Kenneth Offit, MD, MPH

and Mark Robson, MD

3:00-3:15pm BREAK

3:15-4:30pm Global Prize Presentation and Keynote

Kenneth Offit, MD, MPH

BRCA at 30: Phenotype, penetrance and populations

4:30-5:00pm Wrap Up and Evaluations

End of accredited portion

5:00-6:30pm Breakthroughs & Discoveries Panel moderated by

Jill Werman Harris:

featuring Susan Domchek, MD, Kenneth Offit, MD, MPH,

Gilbert Welch, MD, Clare Turnbull, MD, PhD, FRCP,

FRCPath, MFPH

This lay session is open to the public.

Registration Information



This conference is FREE but we strongly recommend registration. Registration is required for continuing education credits.

ACCREDITATION AND DESIGNATION OF CREDIT

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Nurse/Nurse Practitioners

The program will award 12.5 NCPD hours

Physicians

Penn Medicine designates this live activity for a maximum of 12.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 12.5 Category 1 credits for completing this activity.

Genetic Counselors

This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

CANCELLATION POLICY

The University reserves the right to cancel or postpone any activity due to unforeseen circumstances. In the event of cancellation or postponement, the University will not be responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines, or travel agencies.

SERVICES FOR THE DISABLED

If special arrangements are required for an individual with a disability to attend this meeting, please contact basserinfo@pennmedicine.upenn.edu by April 29, 2024.

SPECIAL REQUESTS


If special requests for food or other logistics are required, contact basserinfo@pennmedicine.upenn.edu by April 29, 2024.

NONDISCRIMINATION STATEMENT

The University of Pennsylvania values diversity and seeks talented students, faculty and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, gender identity, religion, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admissions policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to: Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Sansom Place East, Suite 228, Philadelphia, PA 19104-6106 or 215.898.6993 (Voice) or 215.898.7803 (TDD).

Visiting Information

PENN MEDICINE CAMPUS MAP



HOTEL

A block of rooms has been reserved at the Sheraton Philadelphia University City Hotel at a special group rate of \$199 per night.

Rooms must be reserved by April 13, 2024 to take advantage of the group rate.

RESERVE YOUR ROOM

COVID GUIDELINES

Penn Medicine's COVID guidelines for visitors to campus can be found here: https://www.pennmedicine.org/coronavirus/visitation-policy-and-guidelines

PARKING


Parking will not be available on the medical campus, but public self-pay parking lots available in the University City vicinity can be found at:

- Drexel University Parking Lot 34th and Market Streets
- University of Pennylvania Parking Lot 34th and Chestnut Streets
- University of Pennsylvania Parking Lot 38th and Walnut Streets

For more information, visit http://cms.business-services.upenn.edu/parking/

PUBLIC TRANSPORTATION

The SEPTA Penn Medicine Station (formerly University City Station) is within walking distance of the medical campus. For more information, visit www.septa.org.



The Basser Center for BRCA is the first comprehensive center for the research, treatment and prevention of BRCA-related cancers. Devoted to advancing care for people affected by BRCA mutations, the Basser Center's unique model provides funding for collaborative research, education and outreach programs around the world.

WE TAKE CANCER PERSONALLY.



